Key facts
- This page summarizes Michael Derby's Form 4 filing for PaxMedica, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Nov 2023, 16:08.
Michael Derby - 27 Nov 2023 Form 4 Insider Report for PaxMedica, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 27 Nov 2023
- Net transaction value
- -$190
- SEC form
- 4
- Accepted by SEC
- 29 Nov 2023, 16:08:20 UTC
- Prior SEC filing
- 30 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen D. Sheldon, Jr. Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Derby filed Form 4 for PaxMedica, Inc. on 29 Nov 2023.
Change
- Previous filing in this sequence was filed on 30 Oct 2023.
- Current net transaction value: -$190.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PXMD
transaction
Common Stock
Sale
- Transaction value
- $190
- Shares
- -185
- Change %
- -0.72%
- Price
- $1.03*
- Shares after
- 25,650
- Date
- 27 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F4
PXMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 431,574
- Date
- 27 Nov 2023
- Ownership
- TardiMed Sciences, LLC
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs.
Footnote F2
The sale price represents the weighted average sale price of the shares sold ranging from $0.97 to $1.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Footnote F3
The reporting person is the managing partner of TardiMed Sciences, LLC and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F4
Reflects a 1-for-17 reverse stock split effective October 30, 2023.